In addition, we found that ECs migration and tube formation mediated by IL-6 and VEGFA were affected not only by VEGFR2 but also by S1PR1, indicating that combined inhibition of VEGFR2 and S1PR1 may be an effective approach for HCC antiangiogenic therapy. This evidence concerns the gene VEGFA and hepatocellular carcinoma.